Peer-Reviewed Translational Research Paves The Way For First-In-Class Autotaxin Inhibitor IOA-289 In Cancer
Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-289 in the ESMO journal Immuno-Oncology and Technology (IOTECH). Read more…